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Objectives: Progastrin-releasing peptide (proGRP) is a promising biomarker for
small cell lung cancer. However, not much is known about how sample processing
and storage conditions affect the stability of proGRP. Here, we examined the
effects of repeated freezeethaw cycles on the stability of proGRP in plasma and
serum.
Methods: Concentrations of proGRP were measured in plasma and serum samples
exposed to two, three, or four freezeethaw cycles and these were compared
with values of corresponding samples exposed to one cycle (baseline). We also
performed the area under the receiver-operating-characteristic curve (AUC)
analysis to determine whether the differences of proGRP concentrations be-
tween each paired plasma and serum sample (DproGRP) can be used for iden-
tifying the samples that have been exposed to multiple freezeethaw cycles.
Results: Concentrations of proGRP gradually decreased in both plasma and serum
samples with increasing numbers of freezeethaw cycles. Reduction rates of
proGRP concentrations were greater in serum than in plasma samples and serum
proGRP levels declined with statistical significance (p < 0.001) up to 10.1% after
four freezeethaw cycles. The DproGRP measurement showed fair accuracy (AUC
Z 0.741) for identifying samples that had been through four freezeethaw cycles.
The sensitivity was 82.8% and specificity was 62.1% at an optimal cut-off point of
> 4.9.
Conclusion:Our study shows that the stability of circulating proGRP is affected in
both plasma and serum samples by repeated freezing and thawing. We also show
that DproGRP could be used for identifying paired plasma and serum samples
subjected to multiple freezeethaw cycles.im).
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
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Recently, circulating progastrin-releasing peptide
(proGRP) has been reported as a putative biomarker of
small cell lung carcinoma (SCLC) [1e4]. ProGRP is a
precursor of gastrin-releasing peptide (GRP), a gastro-
intestinal hormone of the bombesin family [5, 6]. GRP
cannot be used as a biomarker due to its instability (the
half-life of GRP is < 3 min) [7]. However, proGRP is a
stable protein with half-life of 19e28 days [8]. An assay
for serum proGRP showed high sensitivity (47e86%)
and specificity (95e100%) in diagnosing SCLC [1e4].
Testing for plasma proGRP also exhibited high sensi-
tivity (> 80%) and specificity (> 90%) [9].
Circulating proteins can be changed by pre-analytical
treatments such as sample collection, processing, and
cryopreservation conditions [10e13]. To achieve accu-
rate disease diagnosis using circulating proGRP, it is
important to identify sample collection, processing, and
storage variables influencing the stability of proGRP and
to establish reliable protocols. Effects on the stability of
circulating proGRP are especially important in the
collection and management of biobank samples that can
be used for future research. Biobank samples may un-
dergo multiple freezeethaw cycles because of a limited
number of aliquots [14], thereby inducing the instability
of circulating proteins [15,16]. Previous studies showed
that proGRP concentrations were changed in plasma and
serum samples with increasing storage time at 2e6C or
room temperature [17e19]. Serum proGRP concentra-
tion was observed to decrease with the number of
freezeethaw cycles [19]. However, that study was
limited because it involved samples from only two
participants.
In this study, we used dozens of plasma and serum
samples to investigate whether detection of circulating
proGRP is changed by repeated freezing and thawing of
samples. Furthermore, we analyzed the data using area
under the receiver-operating-characteristic curve
(AUC), to determine whether DproGRP can be used to
identify repeated freezing and thawing of paired plasma
and serum samples.2. Materials and methods
2.1. Sample preparation
Whole-blood samples were collected from 30 healthy
volunteers consisting of 15 men (aged between 27 years
and 41 years) and 15 women (aged between 25 years
and 52 years). All volunteers provided written informed
consent. Plasma separator tubes (K2 EDTA tubes; Bec-
ton Dickinson, Franklin Lakes, NJ, USA) and vacutainer
serum separator tubes (SST tubes; Becton Dickinson)
were used to collect the whole blood. Within 20 minutes
after whole-blood collection, all tubes were centrifuged
for 15 minutes at 2,000g at 4C, to obtain plasma andserum samples. Each of the plasma and serum samples
was aliquoted into four 1.5 mL tubes. Each aliquot of
plasma or serum was repeatedly frozen at e70C and
thawed at 37C one, two, three, or four times. The
thawing time at 37C and exposure time at room tem-
perature were recorded.
2.2. Measurement of proGRP concentrations
Levels of proGRP (pg/mL) in plasma and serum
samples were measured, in duplicate, with Architect
ProGRP immunoassays (Abbott Japan, Tokyo, Japan) in
accordance with the manufacturer’s protocol.
2.3. Statistical analysis
Concentrations of proGRP are shown as mean -
 standard deviation. Concentration changes of proGRP
under repeated freezing and thawing conditions (2, 3,
and 4 freezeethaw cycles) are expressed as mean per-
centage changes with a “þ” for increase and a “e” for
decrease, compared with one freezeethaw cycle (base-
line). The statistical significance of proGRP changes
was estimated via paired two-tailed t tests using SPSS
statistical software, Version 13 (SPSS Inc., Chicago, IL,
USA).
Receiver-operating-characteristic (ROC) curve
analysis was performed using MedCalc software for
Windows (MedCalc Software, Ostend, Belgium). The
differences of proGRP concentrations between the
paired plasma and serum samples (plasma proGRP
concentration e serum proGRP concentration;
DproGRP) that were exposed to one freezeethaw cycle
and those exposed to four freezeethaw cycles were
used for this analysis. The results of AUC analysis
were considered excellent for AUC values > 0.9, good
for AUC values between 0.8 and 0.9, fair for AUC
values between 0.7 and 0.8, and poor for AUC values
< 0.7. In all statistical analysis, p values < 0.05 were
regarded as statistically significant.3. Results
3.1. Effect of repeated freezing and thawing of
plasma and serum samples on the stability
of proGRP
Concentrations of proGRP were measured in plasma
and serum samples exposed to two, three, and four
freezeethaw cycles, and the values were compared with
concentrations of proGRP in corresponding samples that
had undergone one freezeethaw cycle (baseline). Con-
centrations of proGRP in both plasma and serum sam-
ples showed a tendency to decease with repeated
freezing and thawing (Table 1). The reductions of
proGRP concentrations in serum samples were greater
than those in plasma samples. Serum proGRP concen-
trations decreased with statistical significance (p <
0.001) up to 10.1% after four freezeethaw cycles (Table
Figure 1. Differences of proGRP concentrations between
paired plasma and serum samples (DproGRP). proGRP Z
progastrin-releasing peptide; DproGRP Z plasma progastrin-
releasing peptide concentrationeserum progastrin-releasing
peptide concentration.
Stability of proGRP 3531). The differences of proGRP concentrations between
each pair of plasma and serum samples (DproGRP),
which were exposed to the same freezeethaw cycle,
increased with increases in the number of freezeethaw
cycles (Figure 1). As shown in Table 2, the thawing time
at 37C and exposure time at room temperature were
similar between plasma and serum samples, meaning
that differences of proGRP concentrations between
paired plasma and serum samples were not induced by
the experimental technique.
3.2. Accuracy analysis of proGRP levels in the
assessment of past freezing and thawing of
plasma and serum samples
We performed ROC curve analysis to identify
whether proGRP levels can be used for assessing the
repeated freezing and thawing history of plasma and
serum samples. For this analysis, we used DproGRP in
samples exposed to one and four freezeethaw cycles;
DproGRP showed fair accuracy (AUC Z 0.741) for
discriminating paired plasma and serum samples
exposed to four freezeethaw cycles (Figure 2)
compared with those subjected to only one cycle.
Additionally, the sensitivity was 82.8% and specificity
was 62.1% at an optimal cutoff point of > 4.9.
3.3. Levels of proGRP in healthy individuals
Concentrations of proGRP were measured using
plasma and serum samples from 30 healthy individuals.
As shown in Table 1, plasma proGRP concentrations
ranged from 27.6 pg/mL to 91.6 pg/mL (mean, 41.3 pg/
mL; standard deviation, 14.9 pg/mL) and serum proGRP
concentrations ranged from 24.3 pg/mL to 83.4 pg/mL
(mean, 36.5 pg/mL; standard deviation, 13.6 pg/mL),
when they were measured after one freezeethaw cycle.
Although these values are not equivalent to those from
fresh samples, our data contribute to the knowledge of
the reference ranges for circulating proGRP in healthy
individuals.Table 1. Changes of proGRP levels in plasma and serum samp
Sample type No. of freezeethaw cycles Range
Plasma 1 27.6e91
2 28.4e84
3 28.6e85
4 26.2e87
Serum 1 24.3e83
2 21.9e79
3 19.5e77
4 18.2e77
*Percentage change, with a “þ” for an increase and a “” for a decrease relative
t test. proGRP Z progastrin-releasing peptide; SD Z standard deviation.4. Discussion
ProGRP is a putative biomarker for SCLC, a subtype
of lung cancer [1e4]. In this study, we assessed the
effects of multiple freezeethaw cycles on the stability of
proGRP in plasma and serum. Concentrations of
proGRP decreased with statistical significance in both
plasma and serum samples that were repeatedly frozen
and thawed two, three, and four times, as compared to
baseline (one freezeethaw cycle) values. In a previous
study, proGRP concentrations were significantly
reduced by repeated freezing and thawing of serum
samples but this was not found in plasma samples [19].
The difference between our results may be due to
experimental variables such as sample size and thawing
conditions. Serum proGRP levels declined up to 10.1%
after four freezeethaw cycles. During repeated freeze-
ethaw cycles, serum samples were incubated at 37C
and room temperature for 11.6 minutes. It has been re-
ported that proGRP concentrations in serum samples
stored for 2 hours at room temperature were reduced by
approximately 10% compared to values in fresh samples
[17]. These findings show that repeated freezing andles exposed to repeated freezeethaw cycles.
proGRP concentrations (pg/mL)
Mean (SD) Change (%)* py
.6 41.3 (14.9) d
.8 40.1 (13.6) 2.9 0.006
.6 40.5 (13.9) 1.9 0.014
.8 40.0 (14.1) 3.1 0.003
.4 36.5 (13.6) d
.9 34.9 (13.6) 4.4 <0.001
.2 34.0 (13.1) 6.8 <0.001
.9 32.8 (13.5) 10.1 <0.001
to baseline (1 cycle); yThe p value was calculated using a paired two-tailed
Table 2. Thawing time at 37C and exposure time at room temperature during repeated freezing and thawing of plasma and
serum samples.
Sample processing
time (min) Sample type
No. of freezeethaw cycles
1 2 3 4
Thawing time at 37C Plasma 2.2 4.2 6.5 8.5
(0.4) (0.4) (0.8) (0.8)
Serum 2.3 4.3 6.7 8.7
(0.8) (0.8) (1.0) (1.0)
Exposure time at room
temperature
Plasma 1.3 1.9 2.4 3.2
(0.2) (0.6) (0.8) (0.9)
Serum 1.1 1.9 2.2 2.9
(0.1) (0.4) (0.7) (1.0)
Data are presented as mean SD.
Figure 2. Accuracy of DproGRP in discriminating plasma
and serum samples that had been exposed to four freezeethaw
cycles, compared with those subjected to one freezeethaw
cycle. DproGRP Z plasma progastrin-releasing peptide con-
centrationeserum progastrin-releasing peptide concentration.
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dation of proGRP than long-term storage at room
temperature.
The degradation rate of proGRP induced by repeated
freezing and thawing was greater in serum samples than
in plasma samples, consistent with a previous finding
[19]. Endogenous proteases such as thrombin are
generated in serum during blood coagulation [17]. This
might be a cause for the difference of stability between
plasma and serum samples. The stability of proGRP was
also much higher in plasma samples than in serum
samples that were stored for a long time at 4C or room
temperature [17e19]. Taken together, these findings
indicate that plasma would be preferred over serum for a
diagnostic test or for further research involving circu-
lating proGRP.
We evaluated whether DproGRP can be used for
detecting repeated freezeethaw cycles of samples,
through AUC analysis. When the cut-off value of
DproGRP was 4.9, sensitivity and specificity for iden-
tifying samples that had undergone four freezeethaw
cycles was 82.8% and 62.1%, respectively. DproGRPshowed fair accuracy (AUC Z 0.741). The assessment
accuracy, sensitivity, and specificity of DproGRP could
be even more elevated when assessing samples exposed
to >4 freezeethaw cycles. Thus, our results demonstrate
that DproGRP could be used for the assessment of the
quality of plasma and serum samples.
Plasma proGRP concentrations ranged from 18.3 to
59.6 pg/mL (median, 40.2 pg/mL) in healthy subjects
(aged between 18 and 50) of Chinese Han ethnicity [20].
In other studies that both used healthy Korean subjects,
plasma proGRP concentrations were 38.7  14.6 pg/mL
(mean  standard deviation) [19] (in subjects aged be-
tween 25 and 52) and 42.5  12.4 pg/mL (in subjects
aged between 45 and 83) [9]. Serum proGRP concen-
trations were found to be 29.4  12.8 pg/mL in healthy
Korean subjects (aged between 25 and 52) [19]. These
studies have provided reference ranges for proGRP
levels in fresh plasma and serum samples from healthy
individuals [9,19,20]. In this study, we provide reference
ranges for proGRP levels derived from frozen samples.
In conclusion, the stability of plasma and serum
proGRP can be affected by multiple freezeethaw cycles.
Thus, biobanks or researchers should minimize the
number of freezeethaw cycles of plasma and serum
samples for research using circulating proGRP.DproGRP
could be used as an indicator to determine whether paired
plasma and serum samples have been repeatedly frozen
and thawed four times or more.Conflicts of interest
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